Two separate research groups demonstrated that the concentration of this biomarker exhibited a significant and early increase after acute myocardial infarction.12,13 The H-FABP assay has been developed as both a quantitative and qualitative method and has undergone evaluation in a significant number of diagnostic cohort studies and several studies have indicated a potential link between H-FABP levels and cardiovascular events, making it a promising biomarker for risk evaluation of cardiovascular events. This evidence concerns the gene FABP3 and myocardial infarction.